Common Stocks - 99.1%
|
|||
Shares
|
Value ($)
|
||
HEALTH CARE - 99.1%
|
|||
Biotechnology - 29.6%
|
|||
Akero Therapeutics, Inc. (a)
|
4,581
|
227,355
|
|
Alnylam Pharmaceuticals, Inc. (a)
|
6,450
|
1,275,939
|
|
ALX Oncology Holdings, Inc. (a)
|
13,700
|
58,362
|
|
Arcellx, Inc. (a)
|
7,333
|
262,815
|
|
Argenx SE ADR (a)
|
2,817
|
1,415,514
|
|
Arrowhead Pharmaceuticals, Inc. (a)
|
5,000
|
138,200
|
|
Ascendis Pharma A/S sponsored ADR (a)
|
3,865
|
378,847
|
|
Beam Therapeutics, Inc. (a)
|
3,014
|
69,865
|
|
Blueprint Medicines Corp. (a)
|
7,423
|
370,111
|
|
Cerevel Therapeutics Holdings (a)
|
14,922
|
353,651
|
|
Cytokinetics, Inc. (a)
|
9,950
|
347,653
|
|
Exact Sciences Corp. (a)
|
7,465
|
624,597
|
|
Icosavax, Inc. (a)
|
19,573
|
151,495
|
|
Intellia Therapeutics, Inc. (a)
|
1,990
|
74,585
|
|
Janux Therapeutics, Inc. (a)
|
11,058
|
121,638
|
|
Keros Therapeutics, Inc. (a)
|
4,185
|
146,935
|
|
Legend Biotech Corp. ADR (a)
|
9,157
|
635,130
|
|
Moonlake Immunotherapeutics (a)(b)
|
3,100
|
178,467
|
|
Natera, Inc. (a)
|
3,853
|
226,287
|
|
Oxford BioMedica PLC (a)
|
84,600
|
345,627
|
|
PTC Therapeutics, Inc. (a)
|
3,536
|
139,672
|
|
Regeneron Pharmaceuticals, Inc. (a)
|
1,076
|
889,303
|
|
Repligen Corp. (a)
|
4,501
|
782,769
|
|
Sarepta Therapeutics, Inc. (a)
|
1,704
|
206,201
|
|
Tyra Biosciences, Inc. (a)
|
6,842
|
104,204
|
|
Vaxcyte, Inc. (a)
|
6,238
|
323,877
|
|
Vertex Pharmaceuticals, Inc. (a)
|
4,674
|
1,628,141
|
|
Verve Therapeutics, Inc. (a)(b)
|
5,934
|
76,371
|
|
Xenon Pharmaceuticals, Inc. (a)
|
2,725
|
106,221
|
|
Zai Lab Ltd. ADR (a)
|
14,654
|
373,237
|
|
Zentalis Pharmaceuticals, Inc. (a)
|
5,954
|
158,138
|
|
12,191,207
|
|||
Health Care Equipment & Supplies - 25.4%
|
|||
Align Technology, Inc. (a)
|
838
|
310,177
|
|
Boston Scientific Corp. (a)
|
36,230
|
1,954,244
|
|
DexCom, Inc. (a)
|
5,847
|
590,430
|
|
ICU Medical, Inc. (a)
|
3,425
|
496,728
|
|
Inspire Medical Systems, Inc. (a)
|
1,941
|
440,374
|
|
Insulet Corp. (a)
|
5,150
|
987,307
|
|
Intuitive Surgical, Inc. (a)
|
3,083
|
963,992
|
|
iRhythm Technologies, Inc. (a)
|
3,524
|
364,276
|
|
Masimo Corp. (a)
|
10,234
|
1,169,542
|
|
Nevro Corp. (a)
|
9,269
|
185,751
|
|
Penumbra, Inc. (a)
|
4,950
|
1,309,275
|
|
ResMed, Inc.
|
3,478
|
555,054
|
|
Stryker Corp.
|
3,111
|
882,124
|
|
Tandem Diabetes Care, Inc. (a)
|
8,929
|
244,297
|
|
10,453,571
|
|||
Health Care Providers & Services - 14.4%
|
|||
agilon health, Inc. (a)
|
36,694
|
650,218
|
|
Centene Corp. (a)
|
19,411
|
1,196,688
|
|
Guardant Health, Inc. (a)
|
9,862
|
385,407
|
|
Humana, Inc.
|
1,823
|
841,551
|
|
LifeStance Health Group, Inc. (a)
|
89,821
|
737,430
|
|
Privia Health Group, Inc. (a)
|
17,400
|
456,750
|
|
UnitedHealth Group, Inc.
|
3,431
|
1,635,146
|
|
5,903,190
|
|||
Health Care Technology - 4.5%
|
|||
Doximity, Inc. (a)
|
6,553
|
156,224
|
|
Evolent Health, Inc. (a)
|
15,428
|
393,568
|
|
Phreesia, Inc. (a)
|
14,429
|
410,794
|
|
Veeva Systems, Inc. Class A (a)
|
4,147
|
865,479
|
|
1,826,065
|
|||
Life Sciences Tools & Services - 17.9%
|
|||
10X Genomics, Inc. (a)
|
18,248
|
946,159
|
|
Bio-Techne Corp.
|
10,073
|
789,723
|
|
Bruker Corp.
|
16,855
|
1,105,688
|
|
Danaher Corp.
|
6,010
|
1,592,650
|
|
Lonza Group AG
|
602
|
333,184
|
|
Olink Holding AB ADR (a)(b)
|
11,274
|
186,359
|
|
Sartorius Stedim Biotech
|
2,397
|
681,247
|
|
Thermo Fisher Scientific, Inc.
|
1,528
|
851,249
|
|
West Pharmaceutical Services, Inc.
|
2,177
|
885,821
|
|
7,372,080
|
|||
Pharmaceuticals - 7.3%
|
|||
Arvinas Holding Co. LLC (a)
|
15,646
|
441,374
|
|
Edgewise Therapeutics, Inc. (a)
|
18,914
|
118,213
|
|
Eli Lilly & Co.
|
1,852
|
1,026,378
|
|
Royalty Pharma PLC
|
40,083
|
1,195,275
|
|
Ventyx Biosciences, Inc. (a)
|
6,569
|
220,062
|
|
3,001,302
|
|||
TOTAL COMMON STOCKS
(Cost $38,998,829)
|
40,747,415
|
||
Money Market Funds - 1.7%
|
|||
Shares
|
Value ($)
|
||
Fidelity Cash Central Fund 5.43% (c)
|
379,488
|
379,564
|
|
Fidelity Securities Lending Cash Central Fund 5.44% (c)(d)
|
330,342
|
330,375
|
|
TOTAL MONEY MARKET FUNDS
(Cost $709,939)
|
709,939
|
||
TOTAL INVESTMENT IN SECURITIES - 100.8%
(Cost $39,708,768)
|
41,457,354
|
NET OTHER ASSETS (LIABILITIES) - (0.8)%
|
(320,734)
|
NET ASSETS - 100.0%
|
41,136,620
|
(a)
|
Non-income producing
|
(b)
|
Security or a portion of the security is on loan at period end.
|
(c)
|
Affiliated fund that is generally available only to investment companies and other accounts managed by Fidelity Investments. The rate quoted is the annualized seven-day yield of the fund at period end. A complete unaudited listing of the fund's holdings as of its most recent quarter end is available upon request. In addition, each Fidelity Central Fund's financial statements are available on the SEC's website or upon request.
|
(d)
|
Investment made with cash collateral received from securities on loan.
|
Affiliate
|
Value,
beginning
of period ($)
|
Purchases ($)
|
Sales
Proceeds ($)
|
Dividend
Income ($)
|
Realized
Gain (loss) ($)
|
Change in
Unrealized
appreciation
(depreciation) ($)
|
Value,
end
of period ($)
|
% ownership,
end
of period
|
Fidelity Cash Central Fund 5.43%
|
-
|
2,576,292
|
2,196,728
|
6,178
|
-
|
-
|
379,564
|
0.0%
|
Fidelity Securities Lending Cash Central Fund 5.44%
|
461,500
|
1,926,940
|
2,058,065
|
779
|
-
|
-
|
330,375
|
0.0%
|
Total
|
461,500
|
4,503,232
|
4,254,793
|
6,957
|
-
|
-
|
709,939
|
|